Key Considerations for Establishing a Rare Disease Business in Korea

Korea offers one of Asia-Pacific's most structured environments for rare disease therapies: a national designation system, a 10% patient copayment for designated conditions, and a pricing pathway built for small populations. Yet the market rarely rewards a standard launch playbook. Having led rare disease launches in Korea for more than a decade, I have seen that success depends less on the product than on how well a company matches its operating model to the way each disease is diagnosed, reimbursed and treated here. What follows are the five considerations I would put in front of any leadership team weighing entry.

1. Match the business model to the disease before choosing a GTM route

Based on how diagnosis, reimbursement and care delivery work across specialties, I group rare disease businesses in Korea into three models. The model should drive the GTM choice, not the other way around.

1) Three rare disease business models

• Evidence-based model. Diagnostic infrastructure is already mature, and genetic confirmation is not a precondition for reimbursement. Growth comes from label and reimbursement expansion built on clinical evidence, and treatment follows defined therapeutic cycles. Rare oncology indications are the clearest example, served by many high-quality specialized centers.

• Platform-based model. Care is concentrated in a small number of specialized centers with strong clinical leadership, and reimbursement rules are well defined. Hemophilia care, for example, is anchored around expert treatment centers, including the Korea Hemophilia Foundation's clinics. PNH therapies require prior review before reimbursement is approved. In these markets, the existing care structure largely sets the rules of engagement.

• Diagnosis-based model. Confirmatory testing is often not fully covered, so the company must help build its own diagnostic pathway. Diagnosis sits in a few expert hospitals, and extending the network to new centers is usually essential. Most ultra-rare diseases fall here: the market is still forming, there are typically no existing treatments, and the company must support the entire patient journey from diagnosis to long-term maintenance.

2) Three GTM routes

• Direct subsidiary. Full control over strategy, pricing and execution, suited to companies with a long-term commitment. Few rare disease companies opened Korean affiliates in recent years, given lingering access uncertainty. As access pathways become more flexible, a subsidiary is again attractive for companies with multiple brands or life-threatening indications in a sufficiently large market.

• Distributor or licensing partner. Faster entry at lower upfront cost, with immediate access to local networks. The trade-off is reduced control over branding, pricing and execution. Scrutinize upfront terms and forecast commitments, and test whether the partner has genuine rare disease experience and can build a specialized team.

• Strategic partnership or joint venture. Shared financial risk and operating cost with a local company. Some recent entrants have chosen JVs over pure licensing. Expect revenue-sharing terms and mutual commitments that can slow decision-making.

3) How the two fit together

Business model	Direct subsidiary	Distributor / licensing	Strategic partnership / JV
Evidence-based	Strong fit for multi-indication portfolios	Workable where the partner has specialty oncology reach	Useful to share evidence-generation cost
Platform-based	Good fit if center relationships can be built directly	Strong fit when the partner already serves the key centers	Moderate fit
Diagnosis-based	Strongest fit: the company must own the patient journey	Highest risk: partners rarely invest in diagnostic build-out	Workable if diagnostic responsibilities are contractually explicit

The most common mistake I see is licensing a diagnosis-based asset to a partner built for an evidence-based or platform-based business. The product launches, but the diagnosed patient pool never grows. A disease-level feasibility study and regulatory due diligence should settle this before any term sheet is signed.

2. Plan pricing, reimbursement and early access as one sequence

Despite strong government support, many orphan drugs still reach reimbursement only through risk-sharing agreements (RSAs) or conditional arrangements. Launch sequencing matters: global price tiering, reference-country exposure and plans for China all shape what Korea can accept. Together, these variables make bottom-line profitability hard to call early.

Orphan drug designation (ODD) does not guarantee a smooth pricing path. Exemption from pharmacoeconomic (PE) evaluation is the key route for most rare disease therapies, but the bar is high. A product generally needs a very small target population, no appropriate therapeutic alternative, a life-threatening indication where robust comparative evidence is hard to generate, and reimbursement in several A8 reference countries. In my experience, demonstrating that a disease is life-threatening is often the hardest test, and the A8 price floor adds a second constraint. These criteria are under active policy review, so check the current rules at the start of every project.

The policy environment is also shifting in the industry's favor. Initiatives linking marketing authorization, HIRA evaluation and NHIS negotiation are shortening timelines, and indication-based pricing is now a live discussion for multi-indication products. Companies that engage early can help shape how these tools are applied.

Given the complexity, local due diligence and a feasibility check with experienced experts pay for themselves. I have seen one product take four submissions over four years before it reached patients. Most of that delay was avoidable with better upfront positioning.

To bridge the gap to reimbursement, companies often use Early Access Programs (EAPs) or Named Patient Programs (NPPs). Korea's framework supports both, but the design choices matter:

• Refund model or free-of-charge (FOC) model

• Operational feasibility at the hospital level

• Perspectives of patients, hospitals and third-party stakeholders

• An exit strategy that reflects disease characteristics, treatment cycles and possible reimbursement delays

3. Treat diagnosis as the growth engine

In rare disease, new patient identification is the primary growth driver, so the diagnostic ecosystem is critical. More than 80% of rare diseases are genetic or congenital. Korea has expanded public support, including KDCA's rare disease diagnostic support program using whole-genome sequencing, but coverage remains uneven. For many conditions, especially newly characterized or ultra-rare ones, testing access and turnaround still limit how quickly patients are found.

Industry has a legitimate role in closing this gap, but diagnostic support must be designed with compliance at its core. Any program touching testing can raise concerns about patient inducement or undue influence on healthcare professionals. The sustainable approaches I have used share three features:

• Independence. Support flows through transparent, arm's-length structures such as research grants to academic institutions or funding to independent laboratories, with no link to prescribing.

• Localized governance. Global SOPs are adapted to Korean law and reviewed by local legal and compliance teams before launch.

• Clinical value. Programs are built around earlier and more accurate diagnosis, which benefits patients regardless of which therapy follows.

  
  

I have built diagnostic screening channels at three rare disease companies, ranging from dried blood spot testing to AI-supported genetic analysis. AI is now changing the economics of patient finding, from variant interpretation to identifying at-risk patients within hospital data under proper governance. Because diagnostic initiatives directly determine early patient identification and commercial success, they deserve the same strategic investment as the launch itself.

4. Build the stakeholder ecosystem early

Rare disease care requires a holistic approach. Beyond patients, physicians and industry, patient advocacy groups (PAGs) and NGOs amplify patient voices and increasingly shape policy discussions. Global advocacy organizations often help local groups build capacity and run awareness initiatives.

Medical societies contribute the scientific evidence that underpins reimbursement and policy decisions. Engaging them early, well before submission, lets clinical and patient perspectives inform the value story rather than react to it. Close coordination across these groups strengthens market access and builds a more sustainable rare disease ecosystem in Korea.

5. Prepare for the gray zone

Creating a new rare disease market means building diagnostic infrastructure, launching a product and ensuring diagnosed patients actually receive treatment, often for the first time in Korea. There is rarely a precedent, and each disease behaves differently. Three gray zones recur:

• Genotype-phenotype mismatch. A patient may carry a pathogenic variant without meeting the clinical criteria in the reimbursement standard, or the reverse. How such cases are judged often shapes the eligible population more than the label does.

• Diagnostic thresholds. Cut-off values for biomarkers or enzyme activity are frequently set for the first time during reimbursement review, and small differences can move patients in or out of coverage.

• Diagnosed but not treated (DUT). Patients may be diagnosed yet remain untreated because of eligibility rules, travel burden, caregiver capacity or physician hesitancy. Each cause needs a different response.

  
  

The financial framework itself is supportive. Korea's national list of designated rare diseases grew from 1,314 in 2024 to 1,389 in 2025, with new additions each year (KDCA via Korea.kr). Once a disease is designated, the NHIS special copayment scheme cuts patients' out-of-pocket share to 10% of total covered costs, compared with 5% for cancer. Lower-income patients can receive further support through KDCA's medical cost assistance program.

These gray zones require continuous clarification with regulators, clinicians and patient groups. Companies that navigate them deliberately will be well placed in a challenging but rewarding market.

Conclusion

Success in Korea's rare disease market starts with an honest answer to one question: which business model does this disease require? That answer should shape the GTM route, the pricing sequence, the diagnostic investment and the stakeholder plan. Companies that combine disease-level market mapping, early engagement with MFDS, HIRA and NHIS, compliant diagnostic partnerships and patient-centered stakeholder work will not only launch successfully. They will improve outcomes for patients who have waited a long time for them.